Switching to pasireotide for acromegaly not well controlled
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests if switching from a standard somatostatin analog to pasireotide can better control acromegaly in patients whose growth hormone and IGF-1 levels remain high. It aims to offer a more effective treatment option for those not responding well enough to initial therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have acromegaly.
- Your current somatostatin analog medicine is not controlling your condition well, with growth hormone levels at 1 μg/L or higher and IGF-1 levels more than 1.3 times the upper limit of normal.
- You are about to start or have already started a second-line treatment, such as pasireotide, pegvisomant alone, or pegvisomant combined with a first-generation somatostatin analog.
- You are willing to be followed for at least 12 months during your second-line therapy.
- You can understand and sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how pasireotide LAR—a drug that controls growth hormone levels—affects bone health in people with acromegaly whose disease is not well-controlled after 6 months of another therapy. It may help patients understand the bone benefits of switching to this treatment.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
This study follows people with acromegaly to better understand how treatments are used in real life and how well they work over time. It may help improve future treatment choices by comparing outcomes across different care patterns.
This early-phase trial tests a new investigational drug called MAR002 in healthy men. The goal is to see how safe the drug is and how the body handles it before moving to larger studies.
This study watches how patients with acromegaly respond to octreotide, a medication given as injections under the skin. Researchers will collect information about how well the treatment works and any side effects you experience.
Hear when a new Acromegaly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.